Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
Neurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab th...
Guardado en:
Autores principales: | Rei Hashimoto, Etsuko Tanabe, Yoshihisa Otsuka, Yukihiro Yoneda, Yasufumi Kageyama |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Karger Publishers
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c3369f45964146f897fd6cf07623e336 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical features of limbic encephalitis with LGI1 antibody
por: Wang ML, et al.
Publicado: (2017) -
Modern management of malignant pleural mesothelioma
por: Patel SC, et al.
Publicado: (2016) -
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Hiroto Yoneda, et al.
Publicado: (2021) -
Malignant Pleural Mesothelioma Nodal Status: Where Are We at?
por: Sara Ricciardi, et al.
Publicado: (2021) -
Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas’s Experience
por: Giuseppe Mangiameli, et al.
Publicado: (2021)